Rohit Rao1,2, Rong Han1, Sean Ogurek1, Chengbin Xue1, Lai Man Wu1, Liguo Zhang1, Li Zhang3, Jian Hu4, Timothy N Phoenix5, Stephen N Waggoner2,6,7, Q Richard Lu1,2,7. 1. Brain Tumor Center, Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 2. Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 3. Department of Environmental and Public Health Sciences, University of Cincinnati, Cincinnati, Ohio, USA. 4. Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5. Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA. 6. Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 7. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Abstract
BACKGROUND: Tumor-associated macrophages/microglia (TAMs) are prominent microenvironment components in human glioblastoma (GBM) that are potential targets for anti-tumor therapy. However, TAM depletion by CSF1R inhibition showed mixed results in clinical trials. We hypothesized that GBM subtype-specific tumor microenvironment (TME) conveys distinct sensitivities to TAM targeting. METHODS: We generated syngeneic PDGFB- and RAS-driven GBM models that resemble proneural-like and mesenchymal-like gliomas, and determined the effect of TAM targeting by CSF1R inhibitor PLX3397 on glioma growth. We also investigated the co-targeting of TAMs and angiogenesis on PLX3397-resistant RAS-driven GBM. Using single-cell transcriptomic profiling, we further explored differences in TME cellular compositions and functions in PDGFB- and RAS-driven gliomas. RESULTS: We found that growth of PDGFB-driven tumors was markedly inhibited by PLX3397. In contrast, depletion of TAMs at the early phase accelerated RAS-driven tumor growth and had no effects on other proneural and mesenchymal GBM models. In addition, PLX3397-resistant RAS-driven tumors did not respond to PI3K signaling inhibition. Single-cell transcriptomic profiling revealed that PDGFB-driven gliomas induced expansion and activation of pro-tumor microglia, whereas TAMs in mesenchymal RAS-driven GBM were enriched in pro-inflammatory and angiogenic signaling. Co-targeting of TAMs and angiogenesis decreased cell proliferation and changed the morphology of RAS-driven gliomas. CONCLUSIONS: Our work identifies functionally distinct TAM subpopulations in the growth of different glioma subtypes. Notably, we uncover a potential responsiveness of resistant mesenchymal-like gliomas to combined anti-angiogenic therapy and CSF1R inhibition. These data highlight the importance of characterization of the microenvironment landscape in order to optimally stratify patients for TAM-targeted therapy.
BACKGROUND: Tumor-associated macrophages/microglia (TAMs) are prominent microenvironment components in human glioblastoma (GBM) that are potential targets for anti-tumor therapy. However, TAM depletion by CSF1R inhibition showed mixed results in clinical trials. We hypothesized that GBM subtype-specific tumor microenvironment (TME) conveys distinct sensitivities to TAM targeting. METHODS: We generated syngeneic PDGFB- and RAS-driven GBM models that resemble proneural-like and mesenchymal-like gliomas, and determined the effect of TAM targeting by CSF1R inhibitor PLX3397 on glioma growth. We also investigated the co-targeting of TAMs and angiogenesis on PLX3397-resistant RAS-driven GBM. Using single-cell transcriptomic profiling, we further explored differences in TME cellular compositions and functions in PDGFB- and RAS-driven gliomas. RESULTS: We found that growth of PDGFB-driven tumors was markedly inhibited by PLX3397. In contrast, depletion of TAMs at the early phase accelerated RAS-driven tumor growth and had no effects on other proneural and mesenchymal GBM models. In addition, PLX3397-resistant RAS-driven tumors did not respond to PI3K signaling inhibition. Single-cell transcriptomic profiling revealed that PDGFB-driven gliomas induced expansion and activation of pro-tumor microglia, whereas TAMs in mesenchymal RAS-driven GBM were enriched in pro-inflammatory and angiogenic signaling. Co-targeting of TAMs and angiogenesis decreased cell proliferation and changed the morphology of RAS-driven gliomas. CONCLUSIONS: Our work identifies functionally distinct TAM subpopulations in the growth of different glioma subtypes. Notably, we uncover a potential responsiveness of resistant mesenchymal-like gliomas to combined anti-angiogenic therapy and CSF1R inhibition. These data highlight the importance of characterization of the microenvironment landscape in order to optimally stratify patients for TAM-targeted therapy.
Authors: Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison Journal: Proc Natl Acad Sci U S A Date: 2019-12-26 Impact factor: 11.205
Authors: Roman Sankowski; Stefanie M Brendecke; Marta Joana Costa Jordão; Giuseppe Locatelli; Yi-Heng Tai; Tuan Leng Tay; Eva Schramm; Stephan Armbruster; Nora Hagemeyer; Olaf Groß; Dominic Mai; Özgün Çiçek; Thorsten Falk; Martin Kerschensteiner; Dominic Grün; Marco Prinz Journal: Science Date: 2019-01-25 Impact factor: 47.728
Authors: Tatsuya Ozawa; Markus Riester; Yu-Kang Cheng; Jason T Huse; Massimo Squatrito; Karim Helmy; Nikki Charles; Franziska Michor; Eric C Holland Journal: Cancer Cell Date: 2014-08-11 Impact factor: 31.743
Authors: Anoop P Patel; Itay Tirosh; John J Trombetta; Alex K Shalek; Shawn M Gillespie; Hiroaki Wakimoto; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; David N Louis; Orit Rozenblatt-Rosen; Mario L Suvà; Aviv Regev; Bradley E Bernstein Journal: Science Date: 2014-06-12 Impact factor: 47.728
Authors: Daniela F Quail; Robert L Bowman; Leila Akkari; Marsha L Quick; Alberto J Schuhmacher; Jason T Huse; Eric C Holland; James C Sutton; Johanna A Joyce Journal: Science Date: 2016-05-20 Impact factor: 47.728
Authors: Timothy R Hammond; Connor Dufort; Lasse Dissing-Olesen; Stefanie Giera; Adam Young; Alec Wysoker; Alec J Walker; Frederick Gergits; Michael Segel; James Nemesh; Samuel E Marsh; Arpiar Saunders; Evan Macosko; Florent Ginhoux; Jinmiao Chen; Robin J M Franklin; Xianhua Piao; Steven A McCarroll; Beth Stevens Journal: Immunity Date: 2018-11-21 Impact factor: 31.745
Authors: Frank Szulzewsky; Andreas Pelz; Xi Feng; Michael Synowitz; Darko Markovic; Thomas Langmann; Inge R Holtman; Xi Wang; Bart J L Eggen; Hendrikus W G M Boddeke; Dolores Hambardzumyan; Susanne A Wolf; Helmut Kettenmann Journal: PLoS One Date: 2015-02-06 Impact factor: 3.240
Authors: Jason K Sa; Nakho Chang; Hye Won Lee; Hee Jin Cho; Michele Ceccarelli; Luigi Cerulo; Jinlong Yin; Sung Soo Kim; Francesca P Caruso; Mijeong Lee; Donggeon Kim; Young Taek Oh; Yeri Lee; Nam-Gu Her; Byeongkwi Min; Hye-Jin Kim; Da Eun Jeong; Hye-Mi Kim; Hyunho Kim; Seok Chung; Hyun Goo Woo; Jeongwu Lee; Doo-Sik Kong; Ho Jun Seol; Jung-Il Lee; Jinho Kim; Woong-Yang Park; Qianghu Wang; Erik P Sulman; Amy B Heimberger; Michael Lim; Jong Bae Park; Antonio Iavarone; Roel G W Verhaak; Do-Hyun Nam Journal: Genome Biol Date: 2020-08-26 Impact factor: 13.583